Remdesivir is an injectable drug | Representational image: Flickr
Remdesivir is an injectable drug | Representational image: Flickr
Text Size:

New Delhi: Data from Gilead, the pharma company producing the drug remdesivir, shows that the use of the drug on Covid-19 patients was associated with significantly improved clinical recovery and a 62 per cent reduction in the risk of mortality compared to standard of care.

The data, released Friday, includes results from 312 patients from Phase III of Gilead’s SIMPLE-Severe trial, which seeks to establish safety and efficacy of the drug, and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as the study.

“The analysis demonstrated that remdesivir treatment was associated with significantly improved clinical recovery and a 62 per cent reduction in the risk of mortality compared to standard of care. Findings from the comparative analysis showed that 74.4 per cent of remdesivir-treated patients recovered by Day 14 versus 59.0 per cent of patients receiving standard of care,” said Gilead in a statement.

However, the company stressed that while the findings were “important”, they needed to be confirmed through clinical trials.

Remdesivir is an investigational drug which hasn’t yet been approved by the Federal Drug Agency. In India, the Ministry of Health and Family Welfare permitted its use under Emergency Use Authorisation for moderate patients.

However, in the first phase of its review, India reduced the remdesivir dosage in clinical management protocol following reports of liver toxicity. The dosage was reduced from six to five days. 


Also read: Coronavirus could become resistant to Covid drug remdesivir, study says

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW


Remdesivir in Covid treatment

Remdesivir is an intravenous drug touted to be promising when it comes to the treatment of Covid-19. It works by inhibiting the coronavirus enzyme that makes copies of the viral Ribonucleic acid (RNA) genome.

In India, the drug is currently administered for five days, with the first dose comprising 200 mg followed by 100 mg doses in the subsequent days.

The drug was first recommended by the US’s National Institute of Allergy and Infectious Diseases (NAID) in April, after a study found that it cut recovery time to 11 days against 15 days on placebo. The preliminary results of this study did not find that remdesivir reduced the mortality rate significantly.

Alternatively, a study conducted by Chinese researchers published in The Lancet said that the benefits of remdesivir were not “statistically significant”, but “patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less.”


Also read: Remdesivir to HCQ: What works against Covid-19, and what doesn’t


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here